Previous 10 | Next 10 |
- Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development- SAN DIEGO and SUZHOU, China, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“...
SAN DIEGO and SUZHOU, China, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced that the first patients have been dosed in a phase 1b/2 clinical trial of the anti-CD137 agonist antibody, ADG106, in combination with the anti-PD-1 antibody,...
- Successful nomination of lead SAFEbody candidates triggers milestone payment - SAN DIEGO and SUZHOU, China, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development ...
Gainers: Galera Therapeutics (NASDAQ:GRTX) +106%. Nuverra Environmental Solutions (NYSE:NES) +33%. CPS Technologies (NASDAQ:CPSH) +24%. Terminix (NYSE:TMX) +21%. Alzamend Neuro (NASDAQ:ALZN) +17%. MIND Technology (NASDAQ:MIND) +17%. Landec Corporation (NASDAQ:LNDC) +13%. Soliton (NASDAQ:SOLY)...
- Posters presented at the 63 rd American Society of Hematology Annual Meeting - SAN DIEGO and SUZHOU, China, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discover...
SAN DIEGO and SUZHOU, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced ...
SAN DIEGO and SUZHOU, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced ...
Gainers Cumberland Pharmaceuticals (NASDAQ:CPIX) +111%. Adagene (NASDAQ:ADAG) +12%. PLAYSTUDIOS (NASDAQ:MYPS) +7%. Verastem (NASDAQ:VSTM) +6%. Chimerix (NASDAQ:CMRX) +6%. Losers: BELLUS Health (NASDAQ:BLU) -7%. LIZHI (NASDAQ:LIZI) -6%. NRX Pharmaceuticals (NA...
Cumberland Pharmaceuticals CPIX +90% on FDA label expansion for pain therapy Pioneer Power Solutions (NASDAQ:PPSI) +66%. First Wave BioPharma (NASDAQ:FWBI) +53% announces independent data monitoring committee provides positive interim safety assessment for part 2 COVID-19 RESER...
Gainers: Cumberland Pharmaceuticals (NASDAQ:CPIX) +131%. Adagene (NASDAQ:ADAG) +12%. Chimerix (NASDAQ:CMRX) +11%. PLAYSTUDIOS (NASDAQ:MYPS) +8%. Verastem (NASDAQ:VSTM) +6%. Losers: BELLUS Health (NASDAQ:BLU) -7%. LIZHI (NASDAQ:LIZI) -5%. NRX Pharmaceuticals (NASDAQ:NRXP) -5%. G...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcel...
SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 20...
BioHarvest Sciences Inc (CNVCF) is expected to report for quarter end 2023-12-31 QS Energy Inc (QSEP) is expected to report for Q4 2023 NKGen Biotech Inc. (NKGN) is expected to report for Q4 2023 Cal-Maine Foods Inc. (CALM) is expected to report for Q3 2024 Davide Campari (DVDCF) ...